Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 6/20 | 0.63 |
| ▸ | ITK | Q08881 | 5/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144035 | 0.86 | LCK (0.63) | LCKITKAURKBCSNK1DGAA | |
| SCHEMBL136247 | 0.79 | LCK (0.67) | LCKITKAURKBGAABUB1 | |
| SCHEMBL141010 | 0.78 | ITK (1.00) | LCKITKAURKB | |
| SCHEMBL141011 | 0.78 | ITK (1.00) | LCKITKAURKB | |
| SCHEMBL178940 | 0.75 | LCK (0.63) | LCKITKAURKBCSNK1DGAA | |
| SCHEMBL139835 | 0.75 | LCK (0.65) | LCKITKAURKBCSNK1DGAA | |
| SCHEMBL139816 | 0.72 | AURKB (0.63) | LCKITKAURKBGAA | |
| SCHEMBL137782 | 0.72 | LCK (0.60) | LCKITKAURKBPDE4BPDE4D | |
| SCHEMBL141420 | 0.71 | LCK (0.64) | LCKITKAURKBCSNK1DGAA | |
| Trifluoroacetic Acid SCHEMBL142297 | 0.71 | LCK (0.57) | LCKITKAURKBCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | LCK 189/4885ITK 2/4885AURKB 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.